OIS@AAO

Powervision

PowerVision Updates on OUS Trials

By Mario Admin | December 5, 2017

The FluidVision AIOL is the first “true shape-changing, fluid-driven intraocular lens (IOL),” according to PowerVision, which means it creates a continuously variable monofocal lens and…

Read More
Mynosys

Mynosys Updates on OUS Zepto Launch

By Mario Admin | December 5, 2017

Zepto – Mynosys’ capsulotomy device used in a one-time method – was launched in India, Australia, Germany, and the US in 2017. The US clinical…

Read More
Avedro

Avedro Updates On Plans to Treat the Cornea

By Mario Admin | December 5, 2017

Avedro uses noninvasive strengthening of the cornea with topical drops and photoactivation without surgery or implants to reshape the cornea through cross-linking. The two major…

Read More
Aciont

Aciont Working on Five-Minute Treatment

By Mario Admin | December 5, 2017

A five-minute noninvasive transscleral treatment: Aciont’s Visual XP is used to deliver molecules passively. Another treatment, Visual XI, is based on iontopheresis and enables the…

Read More
EyeGate

EyeGate Pharma Moving Fast Toward Commercialization

By Mario Admin | December 5, 2017

EyeGate Pharma is taking two technology platforms quickly through to commercialization, CEO Stephen From said. The first is a hyaluronic acid (HA) the company is…

Read More
Novaliq

Novaliq Set to `Transform Ocular Therapies’

By Mario Admin | December 5, 2017

Novaliq’s mission is to “transform ocular therapeutics” using a proprietary water-free platform to accomplish the goal. A key limitation of water-based technologies is bioavailability, which…

Read More
Bio-Tissue

Bio-Tissue Targeting Dry Eye with Prokera

By Mario Admin | December 5, 2017

Bio-Tissue is the pioneer of the birth tissue industry, said CTO Scheffer Tseng. Biotissue is cryopreserved, and boasts anti-inflammation, anti-scarring, anti-angiogenesis, and promotion of wound…

Read More
Jcyte

jCyte Developing Cell-based RP Treatment

By Mario Admin | December 5, 2017

This company has developed a cell-based therapy (jCell) to preserve and restore vision in people with retinitis pigmentosa (RP), although the therapy is potentially applicable…

Read More
Nightstar

Nightstar Taking Many Shots at Retinal Disease

By Mario Admin | December 5, 2017

Nightstar’s mission is to maintain and restore vision in blinding inherited retinal diseases. To that end, the company has seven retinal programs under license. Its…

Read More
agtc

AGTC Eyeing Multiple Shots

By Mario Admin | December 5, 2017

Devoted to developing genetic therapies through the use of vector technologies and dosing for patients with inherited retinal diseases, AGTC has partnered with Biogen and…

Read More
Acufocus Set Out to Beat the Blur

AcuFocus Set Out to Beat the Blur

By Mario Admin | November 28, 2017

The AcuFocus platform differs from other solutions in that others rearrange the blur commonly found with presbyopia and other refractive errors, while the AcuFocus platform…

Read More
EBS Technologies Targeting Glaucoma with Neurostim

EBS Technologies Targeting Glaucoma with Neurostim

By Mario Admin | November 28, 2017

The current standard of care for glaucoma involves reducing intraocular pressure, whether through medication use or surgery, or some combination of the two. But with…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.